Share on StockTwits

Aratana Therapeutics (NASDAQ:PETX) Insider Julia A. Stephanus sold 2,000 shares of the stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $17.33, for a total transaction of $34,660.00. Following the completion of the transaction, the insider now directly owns 119,679 shares of the company’s stock, valued at approximately $2,074,037. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded up 3.71% during mid-day trading on Friday, hitting $17.90. The stock had a trading volume of 141,110 shares. Aratana Therapeutics has a 52-week low of $8.07 and a 52-week high of $29.32. The stock’s 50-day moving average is $14.40 and its 200-day moving average is $17.1. The company’s market cap is $514.8 million.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.01. The company had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.09 million. The company’s revenue for the quarter was up NaN% on a year-over-year basis. On average, analysts predict that Aratana Therapeutics will post $-1.51 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Friday, June 6th. They now have a $23.00 price target on the stock, down previously from $25.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Aratana Therapeutics in a research note on Wednesday, May 14th. They now have a $22.00 price target on the stock, down previously from $30.00. Finally, analysts at Zacks downgraded shares of Aratana Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, April 14th. They now have a $18.40 price target on the stock. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aratana Therapeutics has an average rating of “Buy” and an average price target of $28.40.

Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.